Personalis (PSNL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Lake Street raised the firm's price target on Personalis to $9 from $7 and keeps a Buy rating on the shares after the company reported preliminary Q4 revenue ahead the firm's estimate and consensus. With cash to breakeven, a strong commercial partner, "robust" clinical data, and the potential for multiple reimbursement approvals, the firm views 2025 as "another transformative year" for Personalis, the analyst tells investors.
Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript
Personalis (PSNL) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.51 per share a year ago.
PSNL stock has surged from $1.61 to over $4.00 per share following strong Q2 earnings and increased demand for NeXT Personal MRD test. Personalis reported $22.6M in revenue for Q2, with improved gross margins and increased full-year revenue guidance. Personalis secured Medicare coverage, expanded commercial partnerships, showcased product benefits, settled an IP lawsuit, and strengthened market position.
Personalis (PSNL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Personalis, Inc. (NASDAQ:PSNL ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich Chen - CMO and EVP, R&D Conference Call Participants Madison Pasterchick - Morgan Stanley Vidyun Bais - BTIG Thomas Flaten - Lake Street Arthur He - H.C. Wainwright Operator Good day and welcome to the Personalis Second Quarter 2024 Earnings Conference Call.
Personalis (PSNL) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago.